Eli Lilly

Stories 41 - 44 | << Prev 

FDA Mandates Suicide Risk Assessment in Drug Trials

Danger doesn't lie only in antidepressants

(Newser) - The Food and Drug Administration is now requiring drug companies to monitor suicide warning signs in clinical trials for experimental drugs, the New York Times reports. In the wake of studies showing that antidepressants might increase the risk of self-harm in children and teens, the agency is showing an awareness...

Big Pharma Faces Big Plunge
Big Pharma Faces Big Plunge

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic...

Pooch Prozac Is Just the Start
Pooch Prozac
Is Just the Start

Pooch Prozac Is Just the Start

New focus on depression and anxiety in pets, from dogs all the way down to fish

(Newser) - With Eli Lilly rolling out a chewable, beef-flavored version of its anti-depressant Prozac for dogs whose ears are drooping, the London Times looks at the current thinking on depression and anxiety in pets. Vets say dogs, as pack animals, are prone to separation anxiety, when left alone, and depression, when...

Schizophrenia Drug Offers New Hope
Schizophrenia Drug Offers
New Hope

Schizophrenia Drug Offers New Hope

Works on different brain chemical than its predecessors

(Newser) - The first human trial of a new medication to treat schizophrenia that works fundamentally differently from its predecessors has shown promising results, according to this month's Nature Medicine. The drug targets glutamate rather than dopamine, as do other drugs. Scientists have long known glutamate is involved in schizophrenia.

Stories 41 - 44 | << Prev 
Most Read on Newser